{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:21:00Z","timestamp":1774930860937,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.bpobgyn.2007.08.002","type":"journal-article","created":{"date-parts":[[2007,9,22]],"date-time":"2007-09-22T11:23:45Z","timestamp":1190460225000},"page":"341-353","source":"Crossref","is-referenced-by-count":63,"title":["Hyperprolactinaemia"],"prefix":"10.1016","volume":"22","author":[{"given":"V.K.B.","family":"Prabhakar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2007.08.002_bib1","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.68.8.1902","article-title":"A radioimmunoassay for human prolactin","volume":"68","author":"Hwang","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/edrv-16-3-354","article-title":"Structural variants of prolactin: occurrence and physiological significance","volume":"16","author":"Sinha","year":"1995","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib3","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/S0021-9258(19)69558-X","article-title":"Human prolactin cDNA structural analysis and evolutionary comparisons","volume":"256","author":"Cooke","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0022-2836(03)00367-X","article-title":"The tertiary structure and backbone dynamics of human prolactin","volume":"328","author":"Keeler","year":"2003","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/j.1460-2075.1984.tb01824.x","article-title":"Isolation and characterization of the human prolactin gene","volume":"3","author":"Truong","year":"1984","journal-title":"EMBO J"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.7221563","article-title":"The prolactin gene is located on chromosome 6 in humans","volume":"212","author":"Owerbach","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1022804817104","article-title":"Growth hormone and prolactin \u2013 molecular and functional evolution","volume":"7","author":"Forsyth","year":"2002","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0303-7207(91)90142-F","article-title":"Multihormonal regulation of the human prolactin gene expression from 5000bp of its upstream sequence","volume":"80","author":"Berwaer","year":"1991","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1210\/me.8.5.635","article-title":"Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene","volume":"8","author":"Berwaer","year":"1994","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib10","first-page":"639","article-title":"Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects","volume":"17","author":"Ben-Jonathan","year":"1996","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0167-5699(90)90139-Z","article-title":"Haemopoietic receptors and helical cytokines","volume":"11","author":"Bazan","year":"1990","journal-title":"Immunol Today"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib12","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1073\/pnas.87.18.6934","article-title":"Structural design and molecular evolution of a cytokine receptor superfamily","volume":"87","author":"Bazan","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib13","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1210\/mend-3-9-1455","article-title":"Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells","volume":"3","author":"Djiane","year":"1989","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib14","doi-asserted-by":"crossref","first-page":"13337","DOI":"10.1016\/S0021-9258(17)36838-2","article-title":"Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction","volume":"269","author":"Nagano","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/er.19.3.225","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib16","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1210\/en.136.8.3619","article-title":"Prolactin is a local growth factor in rat mammary tumors","volume":"136","author":"Mershon","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib17","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/sj.onc.1206619","article-title":"Prolactin induces ER alpha-positive and ER alpha-negative mammary cancer in transgenic mice","volume":"22","author":"Rose-Hellekant","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib18","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1210\/en.2002-0187","article-title":"Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin","volume":"144","author":"Kindblom","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib19","first-page":"2591","article-title":"Prolactin synthesis and secretion by human breast cancer cells","volume":"55","author":"Ginsburg","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1172\/JCI119204","article-title":"Prolactin and prolactin receptors are expressed and functioning in human prostate","volume":"99","author":"Nevalainen","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jnci\/91.7.629","article-title":"Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women","volume":"91","author":"Hankinson","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib22","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-04-1870","article-title":"Plasma prolactin concentrations and risk of postmenopausal breast cancer","volume":"64","author":"Tworoger","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/172460080502000207","article-title":"Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer","volume":"20","author":"Lissoni","year":"2005","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/jcem-38-4-646","article-title":"Relation of sleep-entrained human prolactin release to REM-nonREM cycles","volume":"38","author":"Parker","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1210\/jc.81.4.1483","article-title":"Gender differences in the temporal organization of prolactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels \u2013 a clinical research center study","volume":"81","author":"Waldstreicher","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2265.1982.tb03159.x","article-title":"Pulsatile gonadotrophin secretion in hyperprolactinaemic amenorrhoea and the response to bromocriptine therapy","volume":"16","author":"Moult","year":"1982","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/edrv-1-3-295","article-title":"Prolactin secreting pituitary tumours in amenorrheic women: a comprehensive study","volume":"1","author":"Schlechte","year":"1980","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0889-8529(18)30471-7","article-title":"Prolactinomas","volume":"16","author":"Vance","year":"1987","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas; weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2002.01510.x","article-title":"Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas?","volume":"56","author":"Yermus","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2265.1997.2701073.x","article-title":"Psychological distress in patients with hyperprolactinaemia","volume":"47","author":"Reavley","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000012273","article-title":"Emotional aspects of hyperprolactinaemia","volume":"67","author":"Sobrinho","year":"1998","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0889-8545(05)70186-8","article-title":"Polycystic ovary syndrome and hyperprolactinemia","volume":"28","author":"Bracero","year":"2001","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0889-8529(05)70203-6","article-title":"Disorders of prolactin secretion","volume":"30","author":"Molitch","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib35","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0140-6736(98)03356-X","article-title":"Growth hormone and prolactin excess","volume":"352","author":"Colao","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","article-title":"Age-related and gender-related occurrence of pituitary adenomas","volume":"41","author":"Mindermann","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/09513599609023603","article-title":"A study of the clinical differences between women and men with hyperprolactinemia","volume":"10","author":"Ramot","year":"1996","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jc.87.2.457","article-title":"Pituitary disease in MEN Type 1 (MEN1): data from the France-Belgium MEN1 Multicenter Study","volume":"87","author":"Verg\u00e8s","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.gco.0000136500.87452.b0","article-title":"Prolactin and reproductive medicine","volume":"16","author":"Davis","year":"2004","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib41","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","article-title":"Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma","volume":"65","author":"Karavitaki","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1055\/s-0029-1211358","article-title":"Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex","volume":"103","author":"Bonhoff","year":"1995","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.87.2.581","article-title":"Macroprolactinemia revisited: a study on 106 patients","volume":"87","author":"Vallette-Kasic","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clineuro.2006.11.001","article-title":"Imaging of sellar and parasellar lesions","volume":"109","author":"Rennert","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/beem.1999.0030","article-title":"Clinical management of prolactinomas","volume":"13","author":"Webster","year":"1999","journal-title":"Baillieres Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib46","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/278252a0","article-title":"Dopamine inhibits adenylate cyclase in human prolactin secreting adenomas","volume":"278","author":"De Camilli","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib48","doi-asserted-by":"crossref","first-page":"10127","DOI":"10.1016\/S0021-9258(19)81486-2","article-title":"Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells","volume":"263","author":"Vallar","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003495-199549020-00009","article-title":"A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"49","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib50","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","article-title":"Drugs five years later: bromocriptine","volume":"100","author":"Vance","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00003495-198836010-00005","article-title":"Therapeutic applications of bromocriptine in endocrine and neurological diseases","volume":"36","author":"Ho","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib54","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jc.84.7.2518","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib55","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jc.86.11.5256","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2265.1991.tb01731.x","article-title":"Effect of the new dopaminergic agonist CV 205\u2013502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas","volume":"34","author":"Duranteau","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1012884214668","article-title":"Quinagolide in the management of prolactinoma","volume":"3","author":"Schultz","year":"2000","journal-title":"Pituitary"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib58","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","article-title":"Resistance to bromocriptine in prolactinomas","volume":"69","author":"Pellegrini","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib59","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/ncpendmet0290","article-title":"Management of resistant prolactinomas","volume":"2","author":"Olafsdottir","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib60","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1210\/jc.82.7.2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib61","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2265.2006.02493.x","article-title":"Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy","volume":"64","author":"Delgrange","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib62","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ncpendmet0270","article-title":"Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinaemia?","volume":"2","author":"Goffin","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2265.1996.738559.x","article-title":"The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy","volume":"44","author":"Soule","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/eje.0.1400043","article-title":"Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?","volume":"140","author":"Turner","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib65","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1210\/jc.87.7.3180","article-title":"Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome","volume":"87","author":"Losa","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-2001-33619","article-title":"Is there a role for surgery for microprolactinomas?","volume":"12","author":"Wang","year":"2001","journal-title":"Semin Neurosurg"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib67","first-page":"145","article-title":"Hypopituitarism following external radiotherapy for pituitary tumors in adults","volume":"70","author":"Littley","year":"1989","journal-title":"Q J Med"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib68","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/BF01727477","article-title":"Bromocriptine in pregnancy: safety aspects","volume":"65","author":"Krupp","year":"1987","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000180100","article-title":"Follow-up of children born of bromocriptine-treated mothers","volume":"22","author":"Raymond","year":"1985","journal-title":"Horm Res"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib70","first-page":"1121","article-title":"Management of prolactinomas during pregnancy","volume":"44","author":"Molitch","year":"1999","journal-title":"J Reprod Med"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib71","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib72","first-page":"425","article-title":"Prolactin-producing microadenomas in pregnancy","volume":"62","author":"Divers","year":"1983","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0020-7292(86)90099-8","article-title":"Rapid regression through bromocriptine therapy of a suprasellar extending prolactinoma during pregnancy","volume":"24","author":"Tan","year":"1986","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","article-title":"Long-term follow-up of patients with hyperprolactinaemia","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0889-8529(05)70061-X","article-title":"Medical treatment of prolactinomas","volume":"28","author":"Molitch","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib76","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib77","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF03349744","article-title":"Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy","volume":"18","author":"Garcia","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib79","first-page":"700","article-title":"Bromocriptine-induced schizophrenia","volume":"85","author":"Peter","year":"1993","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib80","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4088\/JCP.v64n1008","article-title":"High dose olanzapine and prolactin levels","volume":"64","author":"Karagianis","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib81","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.182.3.199","article-title":"Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review","volume":"182","author":"Wieck","year":"2003","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib82","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1210\/jcem-60-4-764","article-title":"Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal","volume":"60","author":"Moriondo","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib83","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2007.08.002_bib84","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/me.8.3.356","article-title":"Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma","volume":"8","author":"Gellersen","year":"1994","journal-title":"Mol Endocrinol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2007.08.002_bib85","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","article-title":"Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy","volume":"67","author":"Colao","year":"2007","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693407001356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693407001356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T04:08:08Z","timestamp":1629778088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693407001356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S1521693407001356"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2007.08.002","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}